Prediction: U.S. Value Stocks Will Outperform for 10 Years. Which ETFs Should You Buy?

The tradable takeaway is not the decade-long “value wins” thesis; it is that a persistent style rotation would mechanically broaden leadership away from the most crowded duration-sensitive growth names. That benefits small-cap financials, industrials, energy, and select cash-generative software/healthcare, while also modestly lifting exchange/ETF turnover activity for market-structure names like NDAQ. The key distinction is quality: cheap balance sheets with real free cash flow should attract incremental flows, but low-quality cyclicals will not get a free pass.

VFVA is the cleaner expression if rates stay sticky, because it has less small-cap beta and a lower multiple base, so it should hold up better if credit remains tight. VBR carries more downside sensitivity to lending standards, refinancing risk, and recession probabilities; the thesis breaks fastest if spreads widen or if small-business earnings revisions roll over. Near term, any rally in real yields or renewed AI-led earnings upgrades would favor growth and compress the relative upside for both funds.

The consensus may be over-reading a historical pattern and underestimating dispersion within the value bucket. The best winners are not “cheap” stocks but self-funding businesses with capital-return support, where EOG-type energy exposure is more durable than lower-quality value traps. Falsifiers are straightforward: a sustained QQQ relative breakout, a sharp decline in real yields, or a credit event that hits small caps before the factor rotation matures.